GeneDx 

$66.8
0
+$7.3+12.27% Today

Statistics

Day High
66.8
Day Low
64.22
52W High
-
52W Low
-
Volume
158
Avg. Volume
-
Mkt Cap
1.96B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-0.02
0.15
0.32
0.49
Expected EPS
-0.015
Actual EPS
N/A

Financials

-4.92%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
855.08MRevenue
-42.04MNet Income

Analyst Ratings

$148.75Average Price Target
The highest estimate is 170.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow WGS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap18.99B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomic sequencing space with GeneDx.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences offers long-read sequencing technologies, competing with GeneDx in providing comprehensive genomic analysis.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific offers products and services for genetic analysis and sequencing, competing in the same space as GeneDx.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen provides sample and assay technologies for molecular diagnostics, competing with GeneDx in the genetic testing market.
Bionano Genomics
BNGO
Mkt Cap17.42M
Bionano Genomics offers genomic analysis tools, competing with GeneDx in the structural variant detection and analysis market.
Guardant Health
GH
Mkt Cap11.72B
Guardant Health specializes in liquid biopsies and cancer diagnostics, competing with GeneDx in the genetic testing for cancer market.
Exact Sciences
EXAS
Mkt Cap12.25B
Exact Sciences focuses on cancer diagnostics, including genetic testing, competing with GeneDx in the oncology genetic testing space.
Myriad Genetics
MYGN
Mkt Cap748.08M
Myriad Genetics specializes in genetic testing and personalized medicine, directly competing with GeneDx in several genetic testing markets.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is involved in CRISPR gene editing, indirectly competing with GeneDx by offering alternative approaches to genetic diseases.

About

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Show more...
CEO
ISIN
US81663L2007

Listings

0 Comments

Share your thoughts

FAQ

What is GeneDx stock price today?
The current price of WGS.BOATS is $66.8 USD — it has increased by +12.27% in the past 24 hours. Watch GeneDx stock price performance more closely on the chart.
What is GeneDx stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange GeneDx stocks are traded under the ticker WGS.BOATS.
What is GeneDx market cap?
Today GeneDx has the market capitalization of 1.96B
When is the next GeneDx earnings date?
GeneDx is going to release the next earnings report on May 13, 2026.
What were GeneDx earnings last quarter?
WGS.BOATS earnings for the last quarter are 0.14 USD per share, whereas the estimation was 0.1 USD resulting in a +36.8% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is GeneDx revenue for the last year?
GeneDx revenue for the last year amounts to 855.08M USD.
What is GeneDx net income for the last year?
WGS.BOATS net income for the last year is -42.04M USD.
When did GeneDx complete a stock split?
GeneDx has not had any recent stock splits.